1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.

Kobrinsky NL, Letts RM, Patel LR, Israels ED, Monson RC, Schwetz N, Cheang MS

Annals of internal medicine1 Oct 1987Cited by 68 (Europe PMC)

PMID3631784DOI10.7326/0003-4819-107-4-446PepBankPUB-03631784

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In spinal fusion patients, desmopressin reduced operative blood loss by 32.5% versus placebo.
In plain wordsIn spinal fusion patients, desmopressin reduced blood loss versus placebo.
Peptide
Desmopressin
Outcome
DecreaseOperative blood loss
Study
n = 35
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Measurements
Reduction
32.5%
versus placebo
Reduction
547 mL
95% CI 19 to 1075; p = 0.015
Source sentences
Summary
During surgery, desmopressin reduced blood loss by 32.5% (547 mL; 95% confidence interval [CI], 19 to 1075; p = 0.015) and reduced the need for concentrated erythrocyte transfusions by 25.6% (0.86 units; 95% CI, 0.08 to 1.65; p = 0.022).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178407
02HumanRandomized controlled trialEfficacy outcome
In spinal fusion patients, desmopressin reduced erythrocyte transfusion requirements by 25.6% versus placebo.
In plain wordsIn spinal fusion patients, desmopressin reduced transfusion requirements versus placebo.
Peptide
Desmopressin
Outcome
DecreaseErythrocyte transfusion requirements
Study
n = 35
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Measurements
Reduction
25.6%
versus placebo
Reduction
0.86 units
95% CI 0.08 to 1.65; p = 0.022
Source sentences
Summary
During surgery, desmopressin reduced blood loss by 32.5% (547 mL; 95% confidence interval [CI], 19 to 1075; p = 0.015) and reduced the need for concentrated erythrocyte transfusions by 25.6% (0.86 units; 95% CI, 0.08 to 1.65; p = 0.022).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178408
03HumanRandomized controlled trialEfficacy outcome
In spinal fusion patients, desmopressin reduced analgesic treatment duration by 13.1%, without an unadjusted significant difference versus placebo.
In plain wordsIn spinal fusion patients, analgesic treatment duration did not differ significantly with desmopressin versus placebo before adjustment.
Peptide
Desmopressin
Outcome
No significant changeAnalgesic treatment duration
Study
n = 35
Comparator
Placebo
Outcome group
Pain · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Measurements
Reduction
13.1%
versus placebo; p = 0.105
Reduction
34 hours
95% CI -5.2 to 72.7; p = 0.105
Source sentences
Summary
After surgery, desmopressin reduced the duration of treatment with analgesic agents by 13.1% (34.0 hours; 95% CI, -5.2 to 72.7; p = 0.105), presumably by decreasing bleeding in the surgical wound.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178409
04HumanRandomized controlled trialEfficacy outcome
In spinal fusion patients, the desmopressin effect on analgesic treatment duration was significant after adjustment for scoliosis origin.
In plain wordsIn spinal fusion patients, desmopressin reduced analgesic treatment duration versus placebo after adjustment for scoliosis origin.
Peptide
Desmopressin
Outcome
DecreaseAdjusted analgesic treatment duration
Study
n = 35
Comparator
Placebo
Outcome group
Pain · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
When adjusted for the origin of the scoliosis by two-way analysis of variance, this effect was even more evident (p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
After surgery, desmopressin reduced the duration of treatment with analgesic agents by 13.1% (34.0 hours; 95% CI, -5.2 to 72.7; p = 0.105), presumably by decreasing bleeding in the surgical wound.
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178410
05HumanRandomized controlled trialOther
In spinal fusion patients, desmopressin use was among the best predictors of operative blood loss and transfusion requirements.
In plain wordsIn spinal fusion patients, desmopressin use helped predict blood loss and transfusion requirements.
Peptide
Desmopressin
Outcome
Not applicablePredictors of blood loss and transfusion requirements
Study
n = 35
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Multiple regression analysis showed that the best three predictors of blood loss in surgery and transfusion requirements were the bleeding time, glass bead platelet retention, and the use of desmopressin.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178411
06HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin increased factor VIII coagulant activity.
In plain wordsIn spinal fusion patients, desmopressin increased factor VIII coagulant activity.
Peptide
Desmopressin
Outcome
IncreaseFactor VIII coagulant activity
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178401
07HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin increased von Willebrand antigen concentrations.
In plain wordsIn spinal fusion patients, desmopressin increased von Willebrand antigen concentrations.
Peptide
Desmopressin
Outcome
Increasevon Willebrand antigen
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178402
08HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin increased glass bead platelet retention.
In plain wordsIn spinal fusion patients, desmopressin increased glass bead platelet retention.
Peptide
Desmopressin
Outcome
IncreaseGlass bead platelet retention
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178403
09HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin increased prothrombin consumption.
In plain wordsIn spinal fusion patients, desmopressin increased prothrombin consumption.
Peptide
Desmopressin
Outcome
IncreaseProthrombin consumption
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178404
10HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin decreased partial thromboplastin time.
In plain wordsIn spinal fusion patients, desmopressin decreased partial thromboplastin time.
Peptide
Desmopressin
Outcome
DecreasePartial thromboplastin time
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178405
11HumanNon-randomized trialEfficacy outcome
In spinal fusion patients, desmopressin decreased bleeding time.
In plain wordsIn spinal fusion patients, desmopressin decreased bleeding time.
Peptide
Desmopressin
Outcome
DecreaseBleeding time
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
10 micrograms/m2As given in this study (human).
Source sentences
Summary
Preoperative testing showed that desmopressin increased factor VIII coagulant activity, von Willebrand antigen concentrations, glass bead platelet retention, and prothrombin consumption and decreased the partial thromboplastin and bleeding times (p less than or equal to 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients were designated to receive 10 micrograms/m2 of desmopressin, and 18, to receive a placebo.
Report a problemFND-0363178406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.